Art. -Nr.: HY-129098

PFM067

Name: PFM067
Brand: MedChemExpress
SKU: HY-129098
Price: 60.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: DMHCA)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

PFM067 (DMHCA) is an orally active cholestenoic acid amide derivative. PFM067 exhibits antiviral activity against HSV‑2, HSV‑1, and HRV‑A1. PFM067 directly binds the ORD domain of human OSBP with a K_d of 3.96 μM. PFM067 blocks late HSV-2 replication, cell-to-cell fusion, syncytium formation, and infectious progeny production, retains glycoproteins in the cis-Golgi, and may block capsid nuclear egress. PFM067 agonizes LXRβ and inhibits DHCR24, restoring membrane fluidity in diabetic CD34⁺ cells and CAC cells. PFM067 protects retinal vascular/visual function in diabetic mice. PFM067 can be used in research related to herpesvirus infection and type 2 diabetes.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.91%
CAS. Nr.: 79066-03-8
Formel: C₂₆H₄₃NO₂
Molecular Weight:401.63

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

PFM067 Chemical Structure

CAS. Nr.: 79066-03-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[3]^[1]

LXRβ

DHCR24

HSV-1

HSV-2

Alle HSV Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Vero	EC50	1.9 μM	Inhibition of HSV-2 strain MS plaque formation in Vero cells by PFM067 added 24 hrs before viral inoculum and assessed 24 hrs after infection by indirect immunoperoxidase using anti-gD antibody. Inhibition of HSV-2 strain MS plaque formation in Vero cells by PFM067 added 24 hrs before viral inoculum and assessed 24 hrs after infection by indirect immunoperoxidase using anti-gD antibody.	j.antiviral.2023.105634
Vero	EC50	1.3 μM	Inhibition of HSV-2 strain MS plaque formation in Vero cells by PFM067 added at viral inoculum and assessed 24 hrs after infection by indirect immunoperoxidase using anti-gD antibody. Inhibition of HSV-2 strain MS plaque formation in Vero cells by PFM067 added at viral inoculum and assessed 24 hrs after infection by indirect immunoperoxidase using anti-gD antibody.	j.antiviral.2023.105634
Vero	EC50	3.3 μM	Inhibition of HSV-1 strain LV plaque formation in Vero cells by PFM067 added before viral inoculum and assessed 48 hrs post-infection by indirect immunoperoxidase. Inhibition of HSV-1 strain LV plaque formation in Vero cells by PFM067 added before viral inoculum and assessed 48 hrs post-infection by indirect immunoperoxidase.	j.antiviral.2023.105634
Vero	EC50	1.2 μM	Inhibition of HSV-1 strain LV plaque formation in Vero cells by PFM067 added at viral inoculum and assessed 48 hrs post-infection by indirect immunoperoxidase. Inhibition of HSV-1 strain LV plaque formation in Vero cells by PFM067 added at viral inoculum and assessed 48 hrs post-infection by indirect immunoperoxidase.	j.antiviral.2023.105634
MRC5	EC50	1.0 μM	Inhibition of HSV-2 plaque formation in MRC-5 human diploid fibroblasts by PFM067 added before viral inoculum in a plaque reduction assay. Inhibition of HSV-2 plaque formation in MRC-5 human diploid fibroblasts by PFM067 added before viral inoculum in a plaque reduction assay.	j.antiviral.2023.105634
MRC5	EC50	1.1 μM	Inhibition of HSV-2 plaque formation in MRC-5 human diploid fibroblasts by PFM067 added at viral inoculum in a plaque reduction assay. Inhibition of HSV-2 plaque formation in MRC-5 human diploid fibroblasts by PFM067 added at viral inoculum in a plaque reduction assay.	j.antiviral.2023.105634
Vero	CC₅₀	200 μM	Cytotoxicity against Vero cells with CC50 >200 μM in plaque reduction assays for HSV-2 and HSV-1 and in MTS viability assay after 24 or 48 hrs. Cytotoxicity against Vero cells with CC50 >200 μM in plaque reduction assays for HSV-2 and HSV-1 and in MTS viability assay after 24 or 48 hrs.	j.antiviral.2023.105634
MRC5	CC₅₀	50 μM	Cytotoxicity against MRC-5 human diploid fibroblasts with CC50 >50 μM in a plaque reduction assay. Cytotoxicity against MRC-5 human diploid fibroblasts with CC50 >50 μM in a plaque reduction assay.	j.antiviral.2023.105634
HeLa	EC50	0.13 μM	Antiviral activity against HSV-2 strain MS in HeLa cells assessed by plaque reduction after 24 hrs. Antiviral activity against HSV-2 strain MS in HeLa cells assessed by plaque reduction after 24 hrs.	42541847
HeLa	CC₅₀	200 μM	Cytotoxicity against HeLa cells assessed by MTS assay after 24 hrs with CC50 greater than 200 μM. Cytotoxicity against HeLa cells assessed by MTS assay after 24 hrs with CC50 greater than 200 μM.	42541847
HeLa	EC50	1.018 μM	Antiviral activity against HRV-A1 in HeLa cells assessed by immunocytochemical focus reduction. Antiviral activity against HRV-A1 in HeLa cells assessed by immunocytochemical focus reduction.	42541847
HeLa	CC₅₀	50 μM	Cytotoxicity against HeLa cells in AdV-5 antiviral assay with CC50 greater than 50 μM. Cytotoxicity against HeLa cells in AdV-5 antiviral assay with CC50 greater than 50 μM.	42541847

In Vitro

Viral InfectionOthers

Viral Infection

PFM067 inhibits HSV-2 plaque formation in Vero cells, with an EC₅₀ of 1.9 μM when administered before infection and an EC₅₀ of 1.3 μM when administered during infection, and a CC₅₀ > 200 μM^[1].
PFM067 maintains Vero cell viability below 200 μM, with CC₅₀ >200 μM^[1].
PFM067 (16.7 μM) strongly reduces the production of infectious HSV-2 progeny virus in Vero cells^[1].
PFM067 (0.6-50 μM; exposed simultaneously with infection for 12 h, or pre-exposed for 24 h followed by infection for 12 h) inhibits HSV-2-induced syncytium formation in Vero cells and reduces complete and incomplete infection events after pre-exposure^[1].
PFM067 (0.2-16.7 μM) reduces HSV-2-induced syncytium size in Vero cells when added after infection, consistent with inhibition of cell-to-cell fusion^[1].
PFM067 does not prevent the accumulation of intranuclear capsids in HSV-2-infected Vero cells but is associated with the absence of extranuclear virus particles^[1].
PFM067 (EC₉₀; 11 h) causes HSV-2 glycoproteins to be retained in the cis-Golgi apparatus and restricts ICP5 to the nucleus in infected Vero cells^[1].
PFM067 (EC₉₀; 24 h) does not inhibit early ICP8 expression but reduces cytoplasmic ICP5 in HSV-2-infected Vero cells while maintaining gB and gD expression, consistent with a late-stage block^[1].
PFM067 inhibits HSV-1 plaque formation in Vero cells, with an EC₅₀ of 3.3 μM when administered before infection and an EC₅₀ of 1.2 μM when administered during infection; it inhibits HSV-2 replication in MRC-5 fibroblasts, with an EC₅₀ of 1.0 μM when administered before infection and an EC₅₀ of 1.1 μM when administered during infection^[1].
PFM067 inhibits HSV-2 replication in HeLa cells with an EC₅₀ of 0.13 μM, and no cytotoxicity is detected at concentrations up to >200 μM; only at 50 μM does it cause mild LDH release in HeLa and Hep-2 cells^[2].
PFM067 reduces HSV-2 progeny virus production in HeLa cells and shows enhanced antiviral activity when OSBP is silenced^[2].
PFM067 inhibits HRV-A1 replication in HeLa cells with an EC₅₀ of 1.018 μM, but shows no antiviral activity against AdV-5^[2].

Others

PFM067 (compound 3) binds to the ORD domain of human OSBP with a K_d of 3.96 μM^[2].
PFM067 (DMHCA) (10 μM; 16-18 h) restores the membrane fluidity of diabetic human peripheral blood CD34⁺ cells, as measured by FRAP, to non-diabetic baseline levels; it restores the membrane fluidity of diabetic mouse CD45⁺CD11b-CD133⁺FLK1⁺ CACs, as measured by FRAP, to above non-diabetic baseline levels^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[1]

Cell Line:

Vero cells
Concentration:

EC₉₀ (1.9 μM during infection; 4.3 μM before infection)
Incubation Time:

11 h
Result:

Sequestered HSV-2 glycoproteins in the cis-Golgi and restricts ICP5 to nuclei in infected Vero cells.

Western Blot Analysis^[1]

Cell Line:

Vero cells
Concentration:

EC₉₀ (1.9 μM during infection; 4.3 μM before infection)
Incubation Time:

24 h
Result:

Did not inhibit early ICP8 expression but reduces cytoplasmic ICP5 while preserving gB and gD expression in HSV-2-infected Vero cells, consistent with a late-stage block.

In Vivo

Carbohydrate MetabolismLipid MetabolismLocal Vascular Regulation

Carbohydrate Metabolism

Lipid Metabolism

Local Vascular Regulation

PFM067 (DMHCA) (8 mg/kg body weight/day; oral; daily; 6 months after diabetic onset) corrects retinal cholesterol homeostasis and diabetic retinopathy endpoints, suppresses bone marrow and systemic inflammation, and restores hematopoietic progenitor balance in db/db mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Chemical Information

CAS. Nr. 79066-03-8
Appearance Solid
Molecular Weight 401.63
Formel C₂₆H₄₃NO₂
Color White to off-white
SMILES

C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(N(C)C)=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4(C(C[C@H](CC4)O)=CC3)C
Synonyms

DMHCA
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Biochim Biophys Acta Mol Basis Dis

CX3CR1 deficiency promotes resolution of hepatic ischemia-reperfusion injury by regulating homeostatic function of liver infiltrating macrophages. [Abstract]

2024 Jun;1870(5):167130. PMID: 38537684

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 7.69 mg/mL (19.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4899 mL

12.4493 mL

24.8985 mL

5 mM

0.4980 mL

2.4899 mL

4.9797 mL

10 mM

0.2490 mL

1.2449 mL

2.4899 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.77 mg/mL (1.92 mM); Clear solution

This protocol yields a clear solution of ≥ 0.77 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.77 mg/mL (1.92 mM); Clear solution

This protocol yields a clear solution of ≥ 0.77 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (291 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Civra A, et al. Identification of oxysterol synthetic analogs as a novel class of late-stage inhibitors of herpes simplex virus 2 replication. Antiviral Research, 2023, 215: 105634.

[2]. Civra A, et al. Targeting oxysterol-binding protein (OSBP) as a novel strategy to inhibit herpes simplex virus 2 (HSV-2) replication: First structure-activity relationship study of antiviral cholenamide derivatives. European journal of medicinal chemistry. 2026 Nov 15;318:119195.

[3]. Vieira C P, et al. Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes. JCI Insight, 2020.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4899 mL	12.4493 mL	24.8985 mL	62.2463 mL
	5 mM	0.4980 mL	2.4899 mL	4.9797 mL	12.4493 mL
	10 mM	0.2490 mL	1.2449 mL	2.4899 mL	6.2246 mL
	15 mM	0.1660 mL	0.8300 mL	1.6599 mL	4.1498 mL

Bioz

PFM067

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

PFM067

Publications Citing Use of MedChemExpress (MCE) PFM067

Alle HSV Isoform-spezifische Produkte anzeigen